1.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
2.
Worldwide access to treatment for end-stage kidney disease: a systematic review
by Liyanage, Thaminda, MBBS
The Lancet (British edition), 2015, Vol.385 (9981), p.1975-1982
3.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
by Ettehad, Dena, MSc
The Lancet (British edition), 2015, Vol.387 (10022), p.957-967
4.
Global burden of blood-pressure-related disease, 2001
by Lawes, Carlene MM, PhD
The Lancet (British edition), 2008, Vol.371 (9623), p.1513-1518
5.
Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial
by Free, Caroline, Dr
The Lancet (British edition), 2011, Vol.378 (9785), p.49-55
6.
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
by Chow, Clara K, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1035-1042
7.
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs
by Lim, Stephen S, PhD
The Lancet (British edition), 2007, Vol.370 (9604), p.2054-2062
8.
Interpretation of the evidence for the efficacy and safety of statin therapy
by Collins, Rory, Prof
The Lancet (British edition), 2016, Vol.388 (10059), p.2532-2561
9.
A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis
by Avery, Anthony J, Prof
The Lancet (British edition), 2012, Vol.379 (9823), p.1310-1319
10.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised control...
by Lennox, Jeffrey L, Prof
The Lancet (British edition), 2009, Vol.374 (9692), p.796-806
11.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two m...
by Eron, Joseph J, Prof
The Lancet (British edition), 2010, Vol.375 (9712), p.396-407
12.
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
by Eron, Joseph J, Prof
The Lancet infectious diseases, 2011, Vol.11 (12), p.907-915
